Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
Sponsor: Synusight Biotech (Shanghai) Co., Ltd.
Summary
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
Official title: A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-06-15
Completion Date
2027-02
Last Updated
2026-09-01
Healthy Volunteers
Yes
Interventions
SST001
Participants will undergo PET imaging after administration.
Locations (2)
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China